Takayasu arteritis (TA) is a chronic large vessel vasculitis affecting predominantly the aorta
45 and its main branches, as well as the pulmonary arteries (1, 2). Of unknown origin (3) …

To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …

Objective. To analyse the efficacy and tolerance of infliximab in refractory Takayasu arteritis
(TA). Methods. French multicentre retrospective study that included patients with TA. Clinical …

Objective To test the efficacy of Infliximab, a chimeric monoclonal antibody against TNF-α, in
the treatment of Takayasu arteritis. Materials and methods We used infliximab at an initial …

Takayasu arteritis (TA) is a systemic vasculitis that affects large-size vessels such as the
aorta and/or its main branches. Persistent inflammation of TA leads to segmental stenosis …

Abstract Treatment of Takayasu's arteritis remains a demanding challenge to clinicians. In
many patients the course of the disease is characterized by frequent relapses and disease …

Takayasu's arteritis (TAK) is an idiopathic large-vessel vasculitis that usually affects young
females (1). Glucocorticoids are the mainstay of treatment for TAK, although relapses occur …

SIR, Takayasu arteritis (TA) is a chronic, idiopathic, inflammatory disease that primarily
affects large vessels [1]. The management of this disorder is largely unresolved, since a …

Background Takayasu arteritis (TA) is a rare chronic-relapsing granulomatous vasculitis
involving primarily the aorta and its major branches 1. TA is associated with considerable …

Anti-TNF agents are recommended for the treatment of Takayasu's patients who are unable
to taper prednisone despite treatment with a nonbiologic immunosuppressive medication …